ZYBERNO
Stock Report
Updated Sep 1, 2026

NEXGEL, INC. (NXGL)

Healthcare • NASDAQ

$0.36

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
10.0/100
POOR BUSINESS
NEXGEL, INC. (NXGL) scores 10/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-121.2%)
Debt-to-Equity (Solvency Risk):POOR (1.37x)
Operating Margin (Operational Efficiency):CRITICAL (-44.8%)
Return on Capital (Capital Efficiency):CRITICAL (-47.3%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

NEXGEL, INC. (NXGL) stock report — Zyberno Score 10/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.36
Market Cap:$3.22M

Valuation Multiples (3)

P/B Ratio:0.59x
P/S Ratio:0.27x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$6.32M

Price Action & Momentum (3)

Momentum Percentile:2 / 100
% of 52-Week High:12.3%
B. Profitability Assessment

Return Metrics (5)

ROA:-41.1%
Reinvestment Rate:-2.9%
Fundamental Growth Rate (g):1.4%

Margin Analysis (3)

Operating Margin Ttm:-44.8%
Net Margin Ttm:-51.3%
Ebitda Margin:-39.6%

TTM Performance (3)

Gross Margin Ttm:35.1%
Operating Margin Ttm:-44.8%
Net Margin Ttm:-51.3%

Yield Metrics (2)

Earnings Yield:-$125.66
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-110.5%
Latest Earnings Filed:2026-08-17

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):68.0%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:0.43x
Quick Ratio:0.27x
Cash Ratio:0.03x

Leverage Analysis (3)

Debt To Equity Ttm:1.37x
Debt-to-Equity Ratio:1.37x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-167.60x
Times Interest Earned:-167.60

Capital Structure (4)

Working Capital:-8,270,000.00
Cash And Cash Equivalents:492,000.00
Long Term Debt:$2.85M
Net Debt:$3.10M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $12.07M
Linear Growth: 68.0%
📊 Click to view full NXGL Revenue analysis & methodology →
Cost Of Revenue Ttm:$7.83M

Profitability Breakdown (2)

Gross profit TTM: $4.23M
Linear Growth: 100.0%
📊 Click to view full NXGL Gross Profit analysis & methodology →
-$5.40M

Bottom Line Performance (3)

-$6.19M
Income Before Tax:-$6.05M
Ebitda Ttm:-4,784,000.00

Operating Expenses (5)

Operating Expenses:9,635,000.00
R And D Expense:22,000.00
Sga Expense:9,614,000.00
Income Tax Expense:$0.00
Interest Expense:20,000.00

Expense Ratios (3)

R And D To Revenue Percentage:0.6%
Sga To Revenue Percentage:260.8%
Ebitda Margin:-39.6%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$26.45M
Current Assets:$6.17M
Ppe Net:1,909,000.00
Goodwill:1,128,000.00
Intangible Assets:$13.49M

Liability Structure (4)

Total Liabilities:20,981,000.00
Current Liabilities:14,440,000.00
Long Term Debt:$2.85M
Short Term Debt:$747.00K

Equity & Capital (3)

Equity:$5.47M
Retained Earnings:-$25.56M
Common Stock:25,000,000.00

Working Capital Items (3)

Accounts Receivable:1,079,000.00
Inventory:2,303,000.00
Accounts Payable:1,505,000.00

Special Items (2)

Contract Liabilities:2,000.00
Stock Based Compensation:143,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$1.42M-$1.38M

Investment Activities (1)

Investing Cash Flow:-$9.00K

Financing Activities (3)

Financing Cash Flow:$1.58M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:618,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-0.71
-$0.71
Earnings Per Share Ttm:-$0.69

Revenue & Cash Per Share (2)

Sales Per Share Ttm:1.34
Operating Cash Flow Per Share:-$0.15

Book Value & Capital (2)

Book Value Per Share:$0.61
Cash Per Share:0.05

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.80x
Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:11.18x
Days Sales Outstanding Ttm:32.64

Inventory Management (2)

Inventory Turnover Ttm:3.40x
Days Inventory Outstanding Ttm:107.30

Payables & Cash Cycle (2)

Days Payable Outstanding:70.12
Cash Conversion Cycle:69.82
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:40.00
Quality Score:25.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:-2.9%
Fundamental Growth Rate (g):1.4%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):68.0%

Other Growth Rates (2)

Gross Profit Growth Rate (Linear):100.0%
Book Value Growth Rate (Linear):-12.1%
C. Company Profile & Context

Corporate Information (6)

Symbol:NXGL
Company Name:NEXGEL, INC.
Sector:Healthcare
Industry:Medical Devices
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:9.01M
Shares Outstanding Basic:9.01M
Shares Outstanding Diluted:9.01M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 18:37:04 UTC
Data Timestamp:2026-08-22T04:02:35.935417
Scroll to Top